Home > Insider Trading > Filing (0001764013-24-000134)

Filing Details

Accession Number:: 0001764013-24-000134
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-07-19 17:38:04
Reporting Period:: 2024-07-17

Accepted Time:: 2024-07-19 17:38:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1764013	Immunovant Inc.	IMVT	Biological Products, (No Disgnostic Substances) (2836)	832771572

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1796290	G. Julia Butchko	C/O Immunovant, Inc. 320 W 37Th Street, 6Th Floor New York NY 10018	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-07-17	2,698	$29.64	444,155	No	4	S	Direct
Common Stock	Disposition	2024-07-17	169	$30.55	443,986	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

On April 12, 2023, the holder was granted 100,188 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 6,261 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.